SARS-CoV2 infection is responsible for a complex clinical syndrome, named Coronavirus Disease 2019 (COVID-19), whose main consequences are severe pneumonia and acute respiratory distress syndrome. Occurrence of acute and subacute neurological manifestations (encephalitis, stroke, headache, seizures, Guillain–Barrè syndrome) is increasingly reported in patients with COVID-19. Moreover, SARS-CoV2 immunopathology and tissue colonization in the gut and the central nervous system, and the systemic inflammatory response during COVID-19 may potentially trigger chronic autoimmune and neurodegenerative disorders. Specifically, Parkinson’s disease, multiple sclerosis and narcolepsy present several pathogenic mechanisms that can be hypothetically initiated by SARS-CoV2 infection in susceptible individuals. In this short narrative review, we summarize the clinical evidence supporting the rationale for investigating SARS-CoV2 infection as risk factor for these neurological disorders, and suggest the opportunity to perform in the future SARS-CoV2 serology when diagnosing these disorders.
【저자키워드】 COVID-19, SARS-CoV2, Risk factors, multiple sclerosis, Parkinson’s disease, Neuroinflammation, neurodegeneration, Demyelination, Narcolepsy, sleepiness, 【초록키워드】 serology, stroke, immunopathology, risk factor, headache, SARS-CoV2 infection, Encephalitis, Central nervous system, Autoimmune, severe pneumonia, Neurological disorders, pathogenic mechanism, acute respiratory distress, Parkinson’s disease, neurodegenerative disorders, Gut, Seizures, tissue, disorders, complex, syndrome, systemic inflammatory response, susceptible individuals, clinical evidence, diagnosing, neurological manifestation, consequence, responsible, reported, initiated, increasingly, patients with COVID-19, 【제목키워드】 Neurological disorder, potential risk,